Cancer Precision Medicine
Improve biomarker signature discovery and validation through multi-omics
How do you discover and shortlist cancer-driver events? Are you sure your signature is statistically significant? Is your single 'omics analysis approach introducing bias?
A growing body of evidence suggests integrating multiple 'omics techniques as a better way to understand complex disease processes; identify and prioritize critical driver events; and explain diagnostic, prognostic, and predictive outcomes. Affymetrix offers a complete suite of technologies and reagents that can easily be combined for a multi-omics strategy for your cancer research.
Our solutions are:
- Compatible with limited and challenging sample types (e.g., formalin-fixed, paraffin-embedded tissues)
- Sensitive enough to detect all important genetic and transcriptomic changes
- Economical so more samples can be run and more statistically significant data can be generated